JEMPERLI (dostarlimab) - Endometrial cancer

Reason for request

Clinical Benefit

Insufficient

The Committee deems that the clinical benefit of JEMPERLI 500 mg (dostarlimab), solution for dilution for infusion, is insufficient to justify public funding in view of the available alternatives in the marketing authorisation indication.

Clinical Added Value

Not applicable